In a patient with end‑stage renal disease and stable vital signs but low hemoglobin, what treatment options are available for anemia?

Treatment Options for Anemia in ESRD with Stable Vital Signs

For a hemodynamically stable ESRD patient with low hemoglobin, initiate treatment by first optimizing iron status with intravenous iron supplementation, followed by erythropoiesis-stimulating agents (ESAs) if hemoglobin remains below 10 g/dL despite adequate iron stores. 1, 2

Initial Evaluation and Iron Assessment

Before initiating any anemia therapy, perform a comprehensive laboratory workup to exclude alternative causes beyond erythropoietin deficiency 2:

• Complete blood count with red cell indices, white blood cell count, differential, and platelet count 2
• Absolute reticulocyte count 2
• Serum ferritin and transferrin saturation (TSAT) 2
• Serum vitamin B12 and folate levels 2
• Review peripheral blood smear and assess for occult blood loss, hemolysis, or bone marrow suppression 3

Iron deficiency is nearly universal in hemodialysis patients receiving ESAs without supplemental iron, making iron optimization the critical first step 3.

Iron Supplementation Strategy

Hemodialysis Patients

Target iron parameters before and during ESA therapy: 1, 4

• TSAT >20% or reticulocyte hemoglobin >29 pg/cell
• Ferritin >200 ng/mL (hemodialysis patients)
• Upper safety limit: ferritin ≤500-800 ng/mL and TSAT ≤50% 3, 1

Intravenous iron is required for most hemodialysis patients because oral iron cannot maintain adequate stores given dialysate losses and ESA-stimulated erythropoiesis 3. The NKF-K/DOQI guidelines permit maintenance IV iron administered thrice weekly, twice weekly, weekly, or every other week, delivering 250-1,000 mg within a 12-week period 4.

Preferred regimen: 100 mg iron sucrose weekly is superior to every-other-week dosing because smaller, frequent doses better match ongoing iron losses 4. Iron sucrose may be given in single doses ≤100 mg 4.

Monitor iron status every 3 months during maintenance therapy, waiting at least 7 days after a 200 mg dose before re-measuring parameters 4.

Non-Dialysis and Peritoneal Dialysis Patients

Target iron parameters: 1

• TSAT >20%
• Ferritin >100 ng/mL

Insufficient evidence exists to recommend IV iron when ferritin exceeds 500 ng/mL 1. In early CKD with iron deficiency, iron supplementation alone may improve anemia and delay ESA initiation 5.

Erythropoiesis-Stimulating Agent (ESA) Therapy

Indications and Hemoglobin Targets

Initiate ESA therapy when: 1, 2

• Hemoglobin falls below 10 g/dL after optimizing iron status
• Patient experiences anemia-related symptoms
• Clinical judgment favors treatment for hemoglobin 10-12 g/dL

Target hemoglobin range: 11.0-12.0 g/dL 1. Avoid achieved hemoglobin >12 g/dL due to increased cardiovascular risks demonstrated in randomized trials 1, 2.

Dosing and Administration

FDA-approved starting doses: 6

• Epoetin alfa: 150 units/kg three times weekly or 40,000 units weekly subcutaneously
• Darbepoetin alfa: 2.25 μg/kg weekly or 500 μg every 3 weeks subcutaneously

Target rate of hemoglobin increase: 1.0-2.0 g/dL per month 1. The hemoglobin rise should not exceed 1 g/dL in any 2-week period 1.

Dose adjustments should occur no more frequently than every 2 weeks, with hemoglobin monitoring twice weekly for 2-6 weeks initially 1.

Contraindications and Cautions

Use ESAs with great caution or avoid entirely in patients with: 2

• Active malignancy (especially when cure is anticipated)
• History of stroke
• History of malignancy

Hypertension is not a contraindication but requires appropriate antihypertensive management if it develops during therapy 1. Thromboembolism risk is increased with ESA therapy, requiring clinical vigilance 6.

Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors (HIF-PHIs)

HIF-PHIs represent an alternative oral therapy that upregulates endogenous erythropoietin production and enhances iron utilization 7, 5, 8. Multiple agents (roxadustat, daprodustat, vadadustat, molidustat, enarodustat, desidustat) have demonstrated non-inferiority to ESAs or placebo in achieving hemoglobin targets of 10-12 g/dL 7.

HIF-PHIs may be particularly useful for: 8

• Patients with inflammation causing ESA hyporesponsiveness
• Patients with functional iron deficiency
• Difficult-to-manage populations

However, cardiovascular safety concerns persist, and the 2026 KDIGO guideline recommends ESAs as preferred first-line therapy pending longer-term safety data 9, 10. Regulatory approval varies by region 10.

Management of ESA Hyporesponsiveness

If hemoglobin fails to increase despite adequate ESA dosing, systematically evaluate: 3, 1

1. Iron deficiency (functional or absolute) - most common cause 3
2. Infection or inflammation - increases ferritin, may require higher ESA doses 3
3. Inadequate dialysis 3
4. Hyperparathyroidism with bone marrow fibrosis 3
5. Aluminum toxicity 3
6. Folate or vitamin B12 deficiency - check despite dialysate losses 3
7. Hemolysis - check reticulocyte count 3
8. Malignancy - may require higher ESA doses 3
9. ACE inhibitor use - monitor for possible resistance 3
10. Blood loss - occult or overt 3

For persistent hyporesponsiveness despite correcting treatable causes, individualize therapy considering risks and benefits of declining hemoglobin, continuing ESA at required doses, or blood transfusions 2.

Adjunctive and Alternative Therapies

Ascorbic Acid (Vitamin C)

In ESA-resistant hemodialysis patients with iron overload (ferritin >800 ng/mL, TSAT >30%), IV ascorbic acid 300 mg three times weekly may improve hemoglobin response 11. One trial showed hemoglobin increase from 9.6 to 10.5 g/dL 11.

Red Blood Cell Transfusions

Reserve transfusions for: 2, 12

• Severe symptomatic anemia
• Hemoglobin <7-8 g/dL in hospitalized patients with coronary heart disease (restrictive strategy preferred) 12
• Patients who remain hyporesponsive to ESAs despite correcting treatable causes 2

Avoid liberal transfusion strategies (trigger >10 g/dL) as they provide no mortality benefit and increase transfusion-related complications 12.

Therapies with Limited Evidence

L-carnitine, ultrapure dialysate, statins, pentoxifylline, and vitamin B6 have been studied but lack high-quality evidence of efficacy for anemia management 11.

Critical Pitfalls to Avoid

• Do not initiate ESAs before optimizing iron status - this is the most common cause of treatment failure 3, 1
• Do not use oral iron alone in hemodialysis patients - it fails to maintain adequate stores 3, 4
• Do not continue high-dose iron when ferritin >800 ng/mL or TSAT >50% - risk of toxicity without benefit 3, 1, 4
• Do not target hemoglobin >12 g/dL - increases cardiovascular events and mortality 1, 2
• Do not increase ESA doses more frequently than every 2 weeks - risks overshoot 1
• Do not use every-other-week iron dosing for initial replacement - start with weekly dosing until stores are repleted 4